Epigenetics and Alzheimer’s: Phase I trials begin for epigenetic drug ORY-2001
First subject dosed in Phase I healthy volunteer study to evaluate Oryzon’s (Barcelona, Spain) oral epigenetic drug for the treatment of Alzheimer’s disease.
Please sign in or register for FREE to view this content
Sign in to EpigenomicsNet
Register to EpigenomicsNet – the epigenetics and epigenomics network
EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.